Skip to contentR
Roivant Sciences Ltd.
R
ROIVRoivant Sciences Ltd. Q2 2025 · 10-Q
Revenue$1.57M$1.57M−64.9% vs Q2 2024 Net Income-$113.52M-$113.52MN/M vs Q2 2024 EPS Diluted-$0.17-$0.17N/M vs Q2 2024 Operating Income-$306,233,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Roivant Sciences Ltd. · CIK 1635088 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$193,512,000N/M Margins · derivedOperating margin-19492.9%−11856.8 pt vs Q2 2024
Net margin-7225.9%−2082.1 pt vs Q2 2024
ended Sep 30, 2025 · filed Nov 10, 2025 · 41 d after period end